Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer

被引:11
|
作者
Yun, Chen [2 ]
Gang, Li [1 ]
Gu Rongmin [1 ]
Xu, Wen [1 ]
Ming Xuezhi [1 ]
Chen Huanqiu [1 ]
机构
[1] Nanjing Med Univ, Dept Gen Surg, Gastr Tumor Ctr, Jiangsu Canc Hosp,Affiliated Canc Hosp, Nanjing 210009, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210009, Jiangsu, Peoples R China
基金
中国博士后科学基金;
关键词
Her2; Her3; Met; gastric cancer; BREAST-CANCER; TARGETED THERAPIES; RECEPTOR; RESISTANCE; MECHANISMS;
D O I
10.1002/mc.22241
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Various receptor tyrosine kinase (RTK) pathways were verified in many cancers including gastric cancer (GC), We sought to investigate the expression of RTKs including Her2, Her3, and Met and their transduction patterns in human GC. Over-expression of Her2, Her3, and c-Met in human GC was verified by immunohistochemistry leading to constitutive activation of RTK signaling pathways. Combined RTKs expression was valuable indicators for poor prognosis of GC patients. Using ErbB2 specific inhibitor Lapatinib and c-Met specific inhibitor PHA-665752, we further demonstrated that this constitutive activation of RTK signaling is necessary for the survival of GC cells. However, various RTK pattern: Her3/Her2 and Met/Her3 were verified in the transduction growth stimulus from outside via both AKT and MAPK signaling. Moreover, the essential roles of Her3 in both two heterodimers were obtained which showed significantly attenuated growth effect due to Her3 knockdown both in vitro and in vivo. In conclusion, various molecular transduction patterns: Her2/Her3 and Met/Her3 were verified in human GC, and Her3 could serve as a potential target in GC treatment. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1700 / 1709
页数:10
相关论文
共 50 条
  • [41] BINDING OF NEU DIFFERENTIATION FACTOR WITH THE EXTRACELLULAR DOMAIN OF HER2 AND HER3
    HORAN, T
    WEN, J
    ARAKAWA, T
    LIU, NL
    BRANKOW, D
    HU, S
    RATZKIN, B
    PHILO, JS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (41) : 24604 - 24608
  • [42] Effects of HER2 and HER3 on EGFR trafficking and localization - a modelling study
    Resat, H
    Shankaran, H
    Wiley, H
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 13A - 13A
  • [43] Role of her3 mutations on breast cancer oncogenesis
    Mishra, Rosalin
    Kilroy, Mary Kate
    Patel, Hima
    Alanazi, Samar
    Garrett, Joan T.
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [44] HEREGULIN-DEPENDENT REGULATION OF HER2/NEU ONCOGENIC SIGNALING BY HETERODIMERIZATION WITH HER3
    WALLASCH, C
    WEISS, FU
    NIEDERFELLNER, G
    JALLAL, B
    ISSING, W
    ULLRICH, A
    [J]. EMBO JOURNAL, 1995, 14 (17): : 4267 - 4275
  • [45] The upgraded role of HER3 and HER4 receptors in breast cancer
    Koutras, Angelos K.
    Fountzilas, George
    Kalogeras, Konstantine T.
    Starakis, Ioannis
    Iconomou, Gregoris
    Kalofonos, Haralabos P.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 74 (02) : 73 - 78
  • [46] The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors
    Cirstea, Andreea-Elena
    Stepan, Alex Emilian
    Margaritescu, Claudiu
    Zavoi, Roxana Eugenia
    Olimid, Daniel Alin
    Simionescu, Cristiana Eugenia
    [J]. ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (04): : 1269 - 1273
  • [47] The role of nuclear HER3 in breast cancer resistance
    Tang, Patrick Ming Kuen
    Khoo, Ui Soon
    Harris, Adrian L.
    Kong, Anthony
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [48] MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
    Novoplansky, Ofra
    Fury, Matthew
    Prasad, Manu
    Yegodayev, Ksenia
    Zorea, Jonathan
    Cohen, Limor
    Pelossof, Raphael
    Cohen, Liz
    Katabi, Nora
    Cecchi, Fabiola
    Joshua, Ben-Zion
    Popovtzer, Aron
    Baselga, Jose
    Scaltriti, Maurizio
    Elkabets, Moshe
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) : 748 - 762
  • [49] Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies
    Pollock, Netanya I.
    Wang, Lin
    Wallweber, Gerald
    Gooding, William E.
    Huang, Weidong
    Chenna, Ahmed
    Winslow, John
    Sen, Malabika
    DeGrave, Kara A.
    Li, Hua
    Zeng, Yan
    Grandis, Jennifer R.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (20) : 4597 - 4606
  • [50] EGFR inhibitor upregulates HER3 expression and enhances the efficacy of HER3 targeting patritumab deruxtecan (HER3-DXd)
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Sakai, Kazuko
    Goto, Hiroki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Otsuka, Eri
    Okida, Hiroaki
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. CANCER SCIENCE, 2022, 113 : 896 - 896